Literature DB >> 33535476

Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture.

Ryoko Kanno1, Tetsuo Koshizuka1,2, Nozomu Miyazaki1, Takahiro Kobayashi1, Ken Ishioka1, Chiaki Ozaki1, Hideki Chiba3, Tatsuo Suzutani1.   

Abstract

Soybeans and fermented soy-derived foodstuffs contain many functional components and demonstrate various beneficial effects. In this report, we demonstrate the anti-fatty liver effect of miso, a traditional fermented product made from soybeans and rice molded in Aspergillus oryzae and forming a common part of the Japanese diet. After acclimation for 2 weeks, male and female C57BL/6J mice were fed with a normal diet (ND), a high-fat diet (HFD), a HFD containing 5% miso (HFD+M), or a HFD containing 5% pre-fermented miso (HFD+PFM) for 20 weeks. Although mice in the HFD group developed typical fatty liver, the consumption of miso or PFM significantly ameliorated the progression of fatty liver in female mice. The liver weight and the average nonalcoholic fatty liver disease activity score (NAS) were significantly reduced in the HFD+M and HFD+PFM groups. In addition, leptin and resistin levels in the serum were decreased in the HFD+M and HFD+PFM groups. The progression of fatty liver was also prevented by the consumption of miso or PFM in male mice, although there were no decreases in NAS. Therefore, miso appears to be a potential food to prevent lifestyle-related diseases such as metabolic syndrome.

Entities:  

Keywords:  isoflavone; leptin; miso; nonalcoholic fatty liver disease; resistin; soy-derived foodstuffs

Year:  2021        PMID: 33535476      PMCID: PMC7912758          DOI: 10.3390/foods10020291

Source DB:  PubMed          Journal:  Foods        ISSN: 2304-8158


  43 in total

1.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Sumio Watanabe; Etsuko Hashimoto; Kenichi Ikejima; Hirofumi Uto; Masafumi Ono; Yoshio Sumida; Masataka Seike; Yoshiyuki Takei; Tetsuo Takehara; Katsutoshi Tokushige; Atsushi Nakajima; Masashi Yoneda; Toshiji Saibara; Goshi Shiota; Isao Sakaida; Makoto Nakamuta; Toshihiko Mizuta; Hirohito Tsubouchi; Kentaro Sugano; Tooru Shimosegawa
Journal:  Hepatol Res       Date:  2015-04       Impact factor: 4.288

Review 2.  Anti-obesity molecular mechanism of soy isoflavones: weaving the way to new therapeutic routes.

Authors:  Siyu Wang; Yu Wang; Min-Hsiung Pan; Chi-Tang Ho
Journal:  Food Funct       Date:  2017-11-15       Impact factor: 5.396

3.  The Japanese food score and risk of all-cause, CVD and cancer mortality: the Japan Collaborative Cohort Study.

Authors:  Emiko Okada; Koshi Nakamura; Shigekazu Ukawa; Kenji Wakai; Chigusa Date; Hiroyasu Iso; Akiko Tamakoshi
Journal:  Br J Nutr       Date:  2018-06-20       Impact factor: 3.718

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

Review 6.  Genistein and daidzein: different molecular effects on prostate cancer.

Authors:  Mawussi Adjakly; Marjolaine Ngollo; Jean-Paul Boiteux; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

Review 7.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

Review 8.  Possibility of breast cancer prevention: use of soy isoflavones and fermented soy beverage produced using probiotics.

Authors:  Akimitsu Takagi; Mitsuyoshi Kano; Chiaki Kaga
Journal:  Int J Mol Sci       Date:  2015-05-13       Impact factor: 5.923

9.  Assessment of isoflavone aglycones variability in soy food supplements using a validated HPLC-UV method.

Authors:  Alina Uifălean; Anca Farcaş; Maria Ilieş; Simona Codruţa Hegheş; Corina Ionescu; Cristina Adela Iuga
Journal:  Clujul Med       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.